Janus Kinases (JAKs) Inhibitor Drug Global Market Report 2025

The janus kinases (JAKs) inhibitor drug market size has grown rapidly in recent years. It will grow from $5.74 billion in 2024 to $6.42 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth during the historic period was driven by the increasing prevalence of autoimmune diseases, expansion of Janus kinase (JAK) inhibitors’ applications beyond rheumatoid arthritis, the aging global population, and favorable reimbursement policies supporting wider access to treatment.

The janus kinases (JAKs) inhibitor drug market size is expected to see rapid growth in the next few years. It will grow to $9.93 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period is expected to be driven by expanding treatment options for immunological diseases, a rising number of approved indications, increased patient awareness and education, improved accessibility to therapies, and a growing emphasis on immunotherapy. Key trends include a shift toward oral therapies, integration of digital therapeutics, strategic partnerships and collaborations, advances in combination therapies, and heightened investment in research and development.

The rising prevalence of autoimmune diseases is expected to drive the growth of the Janus kinase (JAK) inhibitor drug market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body’s healthy cells and tissues. This increasing prevalence is influenced by genetic factors, as certain predispositions make individuals more susceptible to immune dysfunction. JAK inhibitors target and block specific enzymes involved in immune signaling, thereby reducing inflammation and preventing immune-mediated tissue damage. For instance, in June 2024, a report by the Australian Institute of Health and Welfare revealed that hospitalizations for rheumatoid arthritis in Australia rose to 10,000 in 2021-22, a 25% increase from 8,000 the previous year, corresponding to 39 hospitalizations per 100,000 population. Consequently, the growing prevalence of autoimmune diseases is propelling demand for JAK inhibitor drugs.

Major companies operating in the Janus kinase (JAK) inhibitor drug market are focusing on securing regulatory approvals to expand therapeutic indications, accelerate market entry, and strengthen their competitive position. Regulatory approvals are official authorizations granted by health authorities permitting the marketing and sale of drugs after confirming their safety and efficacy for specific medical conditions. For example, in April 2025, AbbVie Inc., a US-based biopharmaceutical company, received FDA approval for RINVOQ (upadacitinib), an oral JAK1-selective inhibitor, for treating adults with giant cell arteritis (GCA). Upadacitinib works by disrupting the JAK-STAT signaling pathway, which transmits signals from pro-inflammatory cytokines involved in immune-mediated and inflammatory diseases. This approval provides a valuable new treatment option that reduces dependence on glucocorticoids - often linked to significant side effects - thus addressing a critical unmet need in GCA management and improving patient outcomes.

In July 2022, GSK plc, a UK-based pharmaceutical and biotechnology company, acquired Sierra Oncology for $1.9 billion. This acquisition aims to strengthen GSK’s specialty medicines portfolio by gaining access to momelotinib, a differentiated late-stage therapy that addresses significant unmet medical needs in myelofibrosis patients with anemia. The deal expands GSK’s capabilities in hematology and offers meaningful new benefits to patients. Sierra Oncology, based in the US, develops momelotinib, a selective oral inhibitor of Janus kinases (JAK1 and JAK2) and ACVR1, specifically for treating myelofibrosis.

Major players in the janus kinases (jaks) inhibitor drug market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Galapagos NV, Theravance Biopharma Inc., Celon Pharma S.A., Aclaris Therapeutics Inc., Arcutis Biotherapeutics Inc., Dizal (Jiangsu) Pharmaceutical Co. Ltd., Reistone Biopharma Co. Ltd.

North America was the largest region in the janus kinases (JAKs) inhibitor market in 2024. The regions covered in janus kinases (JAKs) inhibitor drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the janus kinases (JAKs) inhibitor drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Janus kinase (JAK) inhibitor drugs are medications designed to block the activity of Janus kinases - enzymes that play a key role in immune system signaling and inflammatory pathways. By inhibiting these enzymes, JAK inhibitors help control overactive immune responses, making them effective in the treatment of autoimmune and inflammatory disorders.

The primary types of Janus kinase (JAK) inhibitors include JAK1, JAK2, JAK3 inhibitors, and other variants. JAK1 inhibitors specifically target the JAK1 enzyme, which is critical in immune cell signaling, and are widely used for managing conditions such as rheumatoid arthritis and atopic dermatitis. These drugs are available in several forms, including selective and non-selective inhibitors, and are administered via oral, injectable, or topical routes. Key therapeutic applications span rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, ulcerative colitis, and atopic dermatitis. The end users include hospitals, home care settings, specialty clinics, and other healthcare facilities.

The janus kinases JAKs inhibitor drug market research report is one of a series of new reports that provides janus kinases JAKs inhibitor drug market statistics, including janus kinases JAKs inhibitor drug industry global market size, regional shares, competitors with a janus kinases JAKs inhibitor drug market share, detailed janus kinases JAKs inhibitor drug market segments, market trends and opportunities, and any further data you may need to thrive in the janus kinases JAKs inhibitor drug industry. This janus kinases JAKs inhibitor drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The janus kinases (JAKs) inhibitor drug market consists of sales of oral tablets, oral capsules, topical formulations, injectable forms, and additional JAK inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.